Furthermore, several clinical trials are ongoing to investigate the vaccination effect of NY-ESO-1 or MAGE-A3 peptide with GM-CSF (NCT00090493), MUC1 peptide with GM-CSF (NCT01232712), or idiotype-KLH and T-cells (NCT01426828) in MM patients (http://www.clinicaltrials.gov/). The gene discussed is CSF2; the disease is Miyoshi myopathy.